Chinook Therapeutics Total Liabilities

Chinook Therapeutics (KDNY) currently reports a total liabilities of $130M as of June 2023. That compares with $94M in the prior-year period — up 40.0% year over year. Use the charts on this page to explore Chinook Therapeutics's total liabilities history and peer comparisons.

Chinook Therapeutics's total liabilities increased from $94M to $130M — a 40.0% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chinook Therapeutics reported $130M in total liabilities as of June 2023. That compares with $94M in the prior-year period — up 40.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chinook Therapeutics, and consider following KDNY for alerts when major investors trade the stock.

Chinook Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KDNY with unrelated industries.